Article Details
Retrieved on: 2018-05-03 00:07:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Casma Therapeutics, Inc., a Cambridge, MA-based biotechnology company harnessing the natural cellular process of autophagy to design new medicines, raised $58.5m in Series A funding. <b>Third Rock Ventures</b> made the investment. Launched in 2018 by Keith Dionne, Ph.D., chief executive officer, ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here